Cataract Clinical Trial
Official title:
A Prospective Evaluation of the Tecnis Symfony Extended Range of Vision Presbyopia Correcting IOL
Advances in cataract surgery and premium IOLs have allowed the ophthalmologist and
optometrist to embrace the fact, as with Lasik patients, that refractive cataract surgery can
allow their patients to be potentially free or less dependent on glasses. However, fewer than
13% of all patients undergoing cataract surgery today choose a premium IOL and of these
approximately 5% are presbyopic IOLs.
The need for greater optometric involvement in cataract surgery is necessary as demand for
cataract surgery increases with the population ageing. According to a recent American
Optometric Association survey, optometrists diagnose, on average, 13 cases of cataracts per
month and refer or co-manage about half of them that are sent for surgery. Since patients
base their decision and selection primarily on doctor recommendations, it is incumbent on the
optometric community to be well informed on the benefits of the Advanced Technology IOLs.
There is currently no data that has been collected comparing Advanced Technology IOLs and
their clinical outcome and acceptance rate among patients co-managed with optometrists. This
pilot study will study the subjective visual symptoms, spectacle independence at various
distances and patient satisfaction after bilateral implantation of the Tecnis Symfony
Extended Range of Vision Advanced Technology IOL in this co-managed care environment. The
primary assessment tool will be a Non-directed Patient Satisfaction and Symptoms
Questionnaire. Initial questions would include; "How satisfied are you with your
spectacle-free vision at distance/intermediate/near?", "Would you choose the same lens
again?" and "Would you recommend the same lens to your relatives and friends". Similarly,
with regard to Photic phenomena / visual symptoms, we would ask "Do you experience any
problems with your vision?" and only follow up with specific questions on severity once the
patient volunteers a specific symptom..
The surgery form will include a question determining the surgeon's satisfaction with the
individual Symfony lens implantation. At last visit the optometric investigator will be asked
about his satisfaction with the performance of the Symfony lens. This will allow monitoring
of any progression of satisfaction as more experience with the lens is obtained.
Symfony Extended Range of Vision IOL was approved by the FDA for commercial use in the United
States in August 2016 demonstrating reasonable assurance of safety and effectiveness (PMA #
P980040 S065). The Symfony IOL diffracts light in a way that allows an extended range of
focus, rather than focusing light at distinct points. Monofocal IOLs have one distinct focus,
which can be set by the surgeon for distance, intermediate, or near. Multifocal IOLs have two
distinct foci for light, at distance and intermediate or near. The proposed optics of the
Symfony are geared toward elongating the eye's focus, rather than producing two distinct
focal points. This elongated focus allows a more continuous spectrum of sharp vision from
distance through intermediate and to near points. Additionally, because light is not focused
at two distinct points, glare and halos should not be as noticeable.
The Symfony IOL offers many advantages to patients, including the absence of a blurry zone of
vision between two distinct focal points. With this comes the possibility of reduced glare
and halos. Additionally, the extended depth of focus, which is more consistent with
accommodating lenses, is not dependent on postoperative movement of the IOL.
An important consideration when selecting this lens is the patient's desired quality of near
vision. The defocus curve of the Symfony lens shows vision between 20/15 and 20/20 from
distance to approximately 66 cm (2 ft). Vision ranges from 20/20 to 20/30 in the intermediate
range of vision until about 50 cm (19 in) and then drops to 20/40 at 40 cm (1 ft). For
patients looking for crisp vision for close reading, this lens may not meet expectations.
This study will simply involve following patients who are implanted with the Tecnis Symfony
Extended Range of Vision IOL. No clinical testing will be performed on the patients other
than those routinely performed by the examining clinician. The only non-routine aspect to the
study is the administration of questionnaires to evaluate symptoms and satisfaction. Thus it
appears that this study introduces no extra risk to the patient over and above that of the
underlying cataract surgery.
The objectives of this single surgical site clinical study are to study the subjective visual
symptoms, spectacle independence at various distances and patient satisfaction after
bilateral implantation of the Tecnis Symfony Extended Range of Vision IOL in a co-managed
care environment (Ophthalmologists and Optometrists).
The patient population for this clinical study will be 200 bilaterally implanted Symfony IOL
patients from 10 optometric practices who fit the inclusion/exclusion criteria for this study
determined at 1 month postoperatively and were referred to a single surgical site.
This study will be a prospective clinical investigation. The study endpoint will be at 3
months postoperatively. Subjects will be recruited from the referring optometrist's current
patient population. Subjects will be enrolled into the study in a sequential manner only
after it has been determined that they are qualified according to the Clinical Protocol
inclusion and exclusion criteria. The study will involve a single surgical site (Principal
Investigator and Surgeon Co-Investigator) and 10 co-managing optometric referring sites
(Co-Investigators). Informed consent, testing study subject questionnaire administration will
be conducted at the co-managing optometric sites. Surgery will be performed at the single
surgical site.
The incidence of subjective visual symptoms, spectacle independence at various distances and
patient satisfaction will be tabulated for each center and for the population as a whole
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04685538 -
Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification.
|
Phase 3 | |
Recruiting |
NCT06060041 -
IC-8 Apthera IOL New Enrollment Post Approval Study
|
||
Recruiting |
NCT05518539 -
Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens
|
||
Recruiting |
NCT05271942 -
Tilt and Tumble vs Divide and Conquer - a Unique Comparison of the Two Cataract Surgery Methods
|
N/A | |
Active, not recruiting |
NCT04778501 -
PMCF Study on Monofocal Toric IOL (PODEYE TORIC) in Asia
|
N/A | |
Completed |
NCT05062564 -
Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye
|
N/A | |
Completed |
NCT03751033 -
Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings
|
N/A | |
Completed |
NCT02529488 -
Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00
|
N/A | |
Completed |
NCT04539548 -
A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract
|
Phase 3 | |
Completed |
NCT03740659 -
Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery
|
Phase 2 | |
Completed |
NCT03494257 -
Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification
|
N/A | |
Completed |
NCT05119127 -
Rotational Stability of Acrysof IQ Vivity Extended Vision Toric IOL and Refractive Visual Outcome.
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03713268 -
Intraoperative OCT Guidance of Intraocular Surgery II
|
||
Completed |
NCT03739528 -
Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery
|
Phase 3 | |
Completed |
NCT02888210 -
A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery
|
Phase 3 | |
Completed |
NCT03356847 -
Evaluation of the Rotational Stability of the Monofocal SISA Implant Following Cataract Surgery
|
N/A | |
Completed |
NCT04332640 -
Clinical Evaluation of the Next Generation Phaco System
|
N/A | |
Recruiting |
NCT03638726 -
Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification
|
Phase 4 | |
Completed |
NCT03050697 -
Evaluation of the Safety and Performance of the HARMONI® Toric Lens
|
N/A |